GlobeNewswire Clinical StudiesOriginal article
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
Phase 2positiveAmpligenPembrolizumabCisplatinPositive
AI Analysis
Summary
AIM ImmunoTech announced positive Phase 2 data from a UPMC-conducted trial of Ampligen combined with Pembrolizumab and Cisplatin for recurrent ovarian cancer, achieving a 50% objective response rate. The trial met its primary endpoint, suggesting potential breakthrough combination therapy.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
50% objective response rate (ORR) in recurrent ovarian cancer trial with Ampligen, Pembrolizumab, and Cisplatin combination
Importance:7/10
Sentiment:
0.80
ovarian cancerimmunotherapycombination therapyclinical trialPhase 2positive data
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on May 7, 2026 12:23 PM